Neurocrine Biosciences Inc.

Neurocrine Biosciences is focused on discovering, developing, and commercializing pharmaceuticals, in diseases with unmet medical needs, through its research and development platform, focused on neurological and endocrine related diseases and disorders. The company's approved products are: INGREZZA? for the treatment of adults with tardive dyskinesia; and ORILISSA? (elagolix), an oral medication for the management of endometriosis associated with moderate to severe pain. The company's clinical development programs include, among others, elagolix for the treatment of Uterine Fibroids, opicapone for the treatment of Parkinson's disease, and NBI-74788 for the treatment of congenital adrenal hyperplasia.
  • TickerNBIX
  • ISINUS64125C1099
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Kenneth Shields ...
  • Laura Chico

All Eyes Toward MDS as VYGR Reports 2Q20 Results

Wedbush Research

Wedbush Morning Call - Aug 10 2020 6:58AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kenneth Shields ...
  • Laura Chico

Neurology Prescription Sales Tracker -- Week Ending 7/31/20

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weighte...

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

Kenneth Shields ...
  • Laura Chico

All Eyes Toward MDS as VYGR Reports 2Q20 Results

Wedbush Research

Wedbush Morning Call - Aug 10 2020 6:58AM

Andreas Argyrides ...
  • Ashiq Mubarack
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kenneth Shields ...
  • Laura Chico

Neurology Prescription Sales Tracker -- Week Ending 7/31/20

NEUROCRINE BIOSCIENCES loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of NEUROCRINE BIOSCIENCES (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 2 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date July 21, 2020, the closing price was USD 131.53 and its potential was estimated at USD 145.61.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch